Search Results

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.

Relievant Medsystems today announced the release of next-generation Intracept ® Access Instruments.

Relievant Medsystems announced the publication of a pooled analysis from three prospective clinical trials that demonstrates the impact of the company’s Intracept® Procedure on significantly reducing the long-term utilization of additional treatments for low back pain.

Relievant Medsystems announced the presentation of four-year pooled results from two prospective clinical trials that further demonstrate the safety, effectiveness and long-term durability of the Intracept® Procedure for patients with vertebrogenic pain.

Relievant Medsystems announced the publication of three-year pooled results from two prospective clinical trials that further validate the safety, effectiveness and long-term durability of the Intracept® Procedure for patients with vertebrogenic pain.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that Palmetto GBA has published a final Local Coverage Determination (LCD) for basivertebral nerve (BVN) ablation that expands access to more than 5 million covered lives.

Relievant Medsystems announced that the International Society for the Advancement of Spine Surgery has published an updated Policy Statement and Literature Review of Intraosseous Basivertebral Nerve ablation in the October issue of the International Journal of Spine Surgery.

Relievant Medsystems announced that basivertebral nerve ablation received a Grade A Quality of Evidence Ranking with High Level of Certainty Regarding Net Benefit in the American Society of Pain & Neuroscience Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain.